Check for updates

UPDATES doi.org/10.1002/adsc.202200030 Advanced Synthesis & Catalysis

Stereoselective Palladium-Catalyzed C(sp^3)–H Mono-Arylation of Piperidines and Tetrahydropyrans with a C(4) Directing Group

Amalia-Sofia Piticari,[a] Daniele Antermite,[a] Joe I. Higham,[a] J. Harry Moore,[a] Matthew P. Webster,[b] and James A. Bull[a,*]

[a] Department of Chemistry, Imperial College London, Molecular Sciences Research Hub, White City Campus, Wood Lane, London W12 0BZ, UK
E-mail: j.bull@imperial.ac.uk
[b] AbbVie Inc., 1 North Waukegan Road, North Chicago, IL 60064, USA

Manuscript received: January 14, 2022; Revised manuscript received: February 25, 2022;
Version of record online: ■■, ■■

Supporting information for this article is available on the WWW under https://doi.org/10.1002/adsc.202200030

© 2022 The Authors. Advanced Synthesis & Catalysis published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Abstract: A selective Pd-catalyzed C(3)–H *cis*-functionalization of piperidine and tetrahydropyran carboxylic acids is achieved using a C(4) amino-quinoline amide auxiliary. High mono- and *cis*-selectivity is attained by using mesityl carboxylic acid as an additive. Conditions are developed with significantly lower reaction temperatures ($\leq 50\,^{\circ}C$) than other reported heterocycle C(sp^3)–H functionalization reactions, which is facilitated by a DoE optimization. A one-pot C–H functionalization-epimerization procedure provides the *trans*-3,4-disubstituted isomers directly. Divergent aminoquinoline removal is accomplished with the installation of carboxylic acid, alcohol, amide and nitrile functional groups. Overall, fragment compounds suitable for screening are generated in 3–4 steps from readily-available heterocyclic carboxylic acids.

Keywords: C–H functionalization; Nitrogen heterocycles; Oxygen heterocycles; Stereoselectivity

Saturated N- and O-heterocycles are widespread motifs in natural products and marketed drugs, as well as valuable building blocks in medicinal chemistry.[1,2] Recently, there has been an increased drive to include saturated heterocycles in screening libraries,[3] as well as an empirically observed link between sp^3-rich structures and lower attrition rate in drug discovery programs.[4] Small saturated heterocycles are advantageous starting points in fragment-based drug discovery due to their low molecular weight, propensity for H-bonding and potential for 3D growth-vectors along the C(sp^3)–H bonds.[5–7] The ability to expediently access any defined substitution pattern would hence be highly desired to elaborate a lead or fragment hit.

Methods to access substituted piperidines and other 6-membered substituted heterocycles primarily rely on prefunctionalized precursors that can undergo cyclisation,[8] ring expansion, or hydrogenation.[9,10] The increased acidity of protons adjacent to the heteroatoms has also enabled the extensive investigation of α-functionalization,[11] however, robust and selective methods for direct ring substitution at other positions are currently scarce.[12,13]

Transition metal-catalyzed C–H functionalization has enormous potential to aid diverse functionalization along C(sp^3)–H bonds from common feedstocks in an expedient fashion.[14,15] Regiocontrol still remains a challenge in saturated heterocycles, where the C(2) position is considerably more activated than C–H bonds away from the heteroatom.[16] Palladium-catalyzed methods have been developed to allow regio- and stereocontrolled functionalization of the more challenging remote positions by exploiting directing groups (Figure 1a).[16,17]

In 2014 we reported the selective C(3) *cis*-arylation of proline derivatives using an aminoquinoline directing group.[18,19] *cis*-Functionalization of piperidines and O-heterocycles with C(2) auxiliaries have subsequently been demonstrated,[20–23] as well as other ring sizes.[24–27] Moving the directing group to the C3-position presents further selectivity requirements. We recently reported the selective C(4) arylation of

© 2022 The Authors. Advanced Synthesis & Catalysis published by Wiley-VCH GmbH



Figure 1. Directed C(sp^3)–H arylation of saturated heterocycles at unactivated positions.

piperidines and pyrrolidines with a C(3) aminoquinoline amide.[28] Maes reported the use of a C(3) picolinamide directing group to form 3,5-syn-disubstituted piperidines,[29] and Sanford developed a C(4) piperidine functionalization using an N(1)-linked directing group.[30] Notably, many of these reports obtained high levels of diastereoselectivity, often due to local steric requirements or stereospecific mechanistic features, though different, and often forcing reaction conditions were required.

Despite ongoing advancements, the C–H functionalization of 6-membered heterocycles with C(4) directing groups remains little studied with only a few isolated examples to date. Achieving high conversion with these substrates presents an additional challenge due to the potential for diarylation. Furthermore, these examples have commonly seen low diastereoselectivity. Yu reported early single examples of arylation,[31] and alkynylation[32] on tetrahydropyrans. In 2016 Yu developed a C(3) arylation of N-heterocycles with a C(4) directing group as part of a broader study using Pd-catalysis with an NHC ligand, with low diastereoselectivity (Figure 1b).[23a] More recently, Yu reported an O-linked C4 directing group with a single example on a tetrahydropyran (2:1 *cis*:*trans*).[33]

Here we report the stereoselective synthesis of *cis*-3,4-disubstituted piperidines and tetrahydropyrans, by C(3) arylation in the presence of a C(4) aminoquinoline amide directing group (Figure 1c). Notably, using moderate temperatures (45–50 °C) achieved high selectivity for mono-*cis* functionalization on the unbiased C(4)-substituted 6-membered ring. To date, this constitutes the first heterocycle C(sp^3)–H functionalization protocol at unactivated positions to not require high temperatures. This method allows generation of attractive fragments for screening as single diastereoisomers.

We first examined N-Boc piperidine 4-carboxylic acid (isonipecotic acid) derivatives bearing bidentate directing groups.[18,34] Low reactivities were observed with amide directing groups containing amine or sulfoxide second coordinating sites. Interestingly, 2-(methylthio)aniline amides resulted in exclusive mono-*trans* arylation in up to 25% yield.[34] Aminoquinoline amide **1** displayed the highest reactivity, and became the focus of our study. However, under conditions previously reported for piperidines with a C(3) directing group,[28a] a mixture of four arylated products were observed (Table 1, entry 1). These were identified as mono-*cis* and mono-*trans* arylated piperidines **2 a** and **3 a**, as well as di-*cis*-*trans* and di-*cis*-*cis* isomers **4 a** and **5 a**.

We optimized the reaction conditions aiming to maximize the yield of **2 a**, with this *cis*-product offering greater potential for downstream diversification. Initially various bases were investigated at 110 °C. Acetate salts biased the reactivity towards the preferential formation of **2 a**, albeit in modest yields.[34] A breakthrough in selectivity was achieved upon significantly lowering the temperature. Chen had previously reported monoarylation of cyclopentanes at ambient temperature using chlorinated solvents.[35] Reacting **1** with K_2CO_3 in CH_2Cl_2 gave <5% yield (Table 1, entry 2) whereas Ag_2CO_3 gave **2 a** exclusively in an encouraging 33% yield over 72 h (Table 1, entry 3). A range of solvents were screened, including substituted aromatics, alcohols and polar aprotic solvents.[34] Halogenated aliphatic and aromatic solvents afforded the highest yields of **2 a** (Table 1, entries 3–7), and α,α,α-trifluorotoluene gave 40% of the mono-*cis* arylation exclusively (Table 1, entry 7). Increasing the temperature in increments of 10 °C led to a peak of 48% yield at 45 °C (Table 1, entry 8). Above this temperature the overall conversion could not be enhanced. Instead, formation of mono-*trans* **3 a** and diarylation to *cis*-*trans* **4 a** was encouraged at the expense of **2 a**.

These are not the final page numbers! ↗↗
© 2022 The Authors. Advanced Synthesis & Catalysis published by Wiley-VCH GmbH

Table 1. Selected optimization for the C–H arylation of piperidine **1**.



Entry[a]	base	solvent	T (°C)	yield (%)[b]				
				2a	**3a**	**4a**	**5a**	**1**
1[c,d]	K_2CO_3	PhMe[e]	110	18	26	10	24	18
2[d]	K_2CO_3	CH_2Cl_2	25	3	–	–	–	88
3	Ag_2CO_3	CH_2Cl_2	25	33	–	–	–	55
4	Ag_2CO_3	DCE	25	35	–	–	–	48
5	Ag_2CO_3	PhCl	25	31	–	–	–	57
6	Ag_2CO_3	*o*-DCB	25	27	–	–	–	62
7	Ag_2CO_3	$PhCF_3$	25	40	–	–	–	52
8	Ag_2CO_3	$PhCF_3$	45	48	5	4	–	37
9	Ag_2CO_3	$PhCF_3$	65	42	7	8	–	36
10	Ag_2CO_3	$PhCF_3$	85	32	8	13	–	38

[a] Reactions on 0.2 mmol scale.
[b] Calculated by ^{1}H NMR spectroscopy using 1,3,5-trimethoxybenzene as internal standard.
[c] 24 h reaction time and 5 mol% $Pd(OAc)_2$.
[d] 30 mol% PivOH used as additive.
[e] 0.3 M concentration of **1**.

Having identified the reaction temperature as a crucial factor, we next examined the effect of additives to increase reactivity, aiming to reduce the reaction time (Table 2).[34] The addition of 30 mol% pivalic acid and adamantane carboxylic acid did not change the reaction profile (Table 2, entries 1–3). Dibenzylphosphate increased conversion, whereas diphenylphosphate and 2-mesitylenecarboxylic acid (MesCOOH) promoted complete consumption of **1** (Table 2, entries 4–6), which would facilitate purification. Moreover, using MesCOOH, the reaction time could be reduced to 24 h, limiting diarylation and providing **2a** in 53% isolated yield (Table 2, entry 7).

Finally, given the interplay of conditions affecting conversion and side product formation, we further refined the reaction conditions in a Design of Experiment (DoE) study.[34] The workflow involved an initial definitive screening of all reaction parameters apart from catalyst loading. This helped confirm the limits of temperature (45 °C) and time (24 h) for a suitable model, as well as demonstrated that the reaction outcome is unaffected by additive loading above 30 mol%. Moreover, aryl iodide loading, Ag_2CO_3 loading and substrate concentration were found to be the main factors affecting yield and selectivity. These parameters were therefore employed in a subsequent custom design screen aimed at maximizing the predicted yield of **2a** whilst minimizing diarylation (see *Supporting Information* for full workflow). Up to 3rd order interactions of these parameters were examined, however, under the set temperature and time conditions no 2nd or higher order interactions were seen. Visualization of 3-dimensional response surfaces of predicted yield against any two of the major factors revealed a defined dome-shaped surface (predicted yield against aryl iodide and base equivalents) with a plateau at 74%. The optimum set of conditions from the plateau gave excellent correlation with the *in-situ* and isolated yields of **2a** (Table 2, entry 8 and Figure 2). Overall, an increased yield and selectivity was achieved at 45 °C along with a reduction in the equivalents of both aryl iodide and silver carbonate base that were required.

With the optimized conditions the reaction scope was investigated (Scheme 1). In the presence of 4-iodoanisole, the mono-*cis* isomer (**2a**) was isolated in 68% yield on 0.4 mmol scale, and 70% yield on 4 mmol scale. Changing the N-protecting group from Boc (**1**) to Cbz (**6**) gave a similar *in-situ* yield, although the N-Cbz group led to a more challenging

© 2022 The Authors. Advanced Synthesis & Catalysis published by Wiley-VCH GmbH

Table 2. Additive screen for the C–H arylation of piperidine **1**.



Entry[a]	Additive	t (h)	yield (%)[b] 2a	3a	4a	5a	1
1	–	72	48	5	4	–	37
2	PivOH	72	44	5	4	–	38
3	Ad-COOH	72	46	3	3	–	41
4	$(BnO)_2PO_2H$	72	55	12	15	2	14
5	$(PhO)_2PO_2H$	72	31	11	36	21	0
6	MesCOOH	72	45	6	11	20	0
7	MesCOOH	24	57 (53)	10	11	9	9
8[c]	MesCOOH	24	72 (68)	8	9	2	5

[a] Reactions on 0.2 mmol scale.
[b] Calculated by ^{1}H NMR spectroscopy using 1,3,5-trimethoxybenzene as internal standard.
[c] 2.0 equiv. ArI, 1.25 equiv. Ag_2CO_3, $PhCF_3$ (0.3 M).



Figure 2. Plot of predicted yield of **2a** *vs* aryl iodide and Ag_2CO_3 equivalents visualized at fixed concentration (0.3 M). DoE study conducted using JMP Pro 14 and a Custom Design Screen.[34]

purification (**9a**). N-Acetyl (**7**) and N-mesyl (**8**) derivatives could also be successfully arylated, albeit in lower yields (**10a**, **11a**). Aryl iodides with various electronic requirements were successfully employed in the reaction, affording piperidines **2b–i** in good yield as single diastereoisomers. Halogen substituents were well tolerated (**2c–e**), providing a useful handle for further functionalization. Boc-protected aniline could be installed in 48% yield (**2j**). *meta*-Substituted and electron-rich trimethoxybenzene and benzodioxole derivatives gave high yields (**2k**, **2l**), as did 2-naphthyliodide (**2m**). 3-Bromo- and 2-fluoro-substituted aryl iodides were tolerated (**2n**, **2o**), though *ortho*-substitution resulted in a reduced yield. Unprotected benzyl alcohol functionality was compatible with the reaction conditions, providing **2q** in 50% yield. Medicinally relevant heterocycles were successfully installed, including N-Ts protected indole (**2p**), as well as pyridines bearing electron-donating or electron-withdrawing groups (**2r**, **2s**). 2-Iodothiophene exhibited an unusually high reactivity, whereby the monoarylation was observed in only trace amounts and *cis-trans* diarylated product (**2t**) was isolated in 55% yield. Similar high reactivity was seen with styryl iodide, leading to an equimolar mixture of all four possible mono- and di-alkenylated piperidines, each isolated in similar yields (19–21%, **2u**).

Minor adaptation of the reaction conditions enabled application to the corresponding tetrahydropyran aminoquinoline amides (Scheme 2). After a screen of additives, 2-mesitylene carboxylic acid (MesCOOH) was also identified as best performing in this case, promoting the highest starting material conversion. A brief DoE study revealed an additive loading of 15 mol% to be optimal in the presence of a similar amount of Ag_2CO_3 as was required with piperidine. A higher loading of aryl iodide could be tolerated and was employed to enhance reactivity, since high *cis*-selectivity was observed for this system, with a

These are not the final page numbers! ↗↗
© 2022 The Authors. Advanced Synthesis & Catalysis published by Wiley-VCH GmbH



Scheme 1. Reaction scope of aryl iodides for C–H arylation of piperidine **1**. Reactions on 0.4 mmol scale. All products were isolated as *cis*-diastereomers unless otherwise stated. [b]Product inseparable from unreacted 6. Yield calculated using 1,3,5-trimethoxybenzene as internal standard. [c]3.0 equiv. ArI and $PhCF_3$ (0.2 M). [d]Represents yield of the *cis-trans* di-arylated piperidine. [e]Each of the four possible alkenylation products were isolated: mono-*cis* (21%), mono-*trans* (20%), di-*cis-cis* (21%) and di-*cis-trans* (19%) alkenylated piperidines. Alkene *E*-geometry preserved in all products.

decreased reactivity towards diarylation. Similarly to the piperidines, higher yields were generally observed for electron-rich coupling partners, and halogens were well-tolerated.

Next we addressed the question of how the minor *trans*-arylated products were formed. Using conditions with elevated temperatures (110 °C) was shown to cause epimerization of *cis*-arylated products, and so reduce dr. On the other hand, resubjecting *cis*-arylated



Scheme 2. Scope of aryl iodides for tetrahydropyran C–H arylation. Reactions on 0.4 mmol scale. All products were isolated as *cis*-diastereomers unless otherwise stated. [a]Isolated as an inseparable 8:1 mixture of mono-*cis* and di-*cis-cis* isomers.

piperidine **2c** to the optimal reaction conditions, in the absence of aryl iodide, gave no *cis*-to-*trans* epimerization at the lower temperature (45 °C). This suggested an alternative route to the *trans*-diastereoisomer via a minor *trans*-palladacycle intermediate.[34,36] To test the viability of a direct *trans*-arylation, we examined a second arylation using a different aryl iodide to provide a stereochemical marker (Scheme 3).



Scheme 3. Studies investigating the diastereochemical outcome in diarylation and a proposed unfavourable intermediate for *trans-trans* arylation of **2c**. Conditions a. **2c** (0.25 mmol), (4-iodophenyl)methanol (2 equiv), Ag_2CO_3 (1.25 equiv), MesCOOH (30 mol%), $Pd(OAc)_2$ (10 mol%), $PhCF_3$ (0.3 M), 45 °C, 24 h.

© 2022 The Authors. Advanced Synthesis & Catalysis published by Wiley-VCH GmbH

From mono-*cis* **2c**, reaction with 4-iodobenzyl alcohol formed both di-*cis*-*trans* (**14**) and di-*cis*-*cis* (**15**) isomers to a similar extent (19% **14** and 15% **15**). The relative stereochemistry at the carbonyl center was maintained, with **14** arising from a second arylation occurring *trans* with respect to the directing group, hence proving the potential for the direct *trans*-arylation. This was further supported by preparation of the *trans*-epimer **16** from **2c** by treatment with NaOH. Arylation now gave only *trans*-*cis*-product **17** as a diastereoisomer of **14**, confirming previous assignments. Interestingly the *trans*-*trans*-diastereoisomer was not observed in this instance, presumably due to the increased strain in the required all-equatorial palladacycle, resulting in unfavourable steric interactions of the directing group with the pre-installed aryl group.

As a direct route to the *trans*-substituted isomers we developed a one-pot arylation-epimerization, leveraging the thermodynamic preference for di-equatorial conformation over the required axial-equatorial conformation in the *cis*-configured compounds. Simple addition of DBU to the reaction mixture after the arylation step promoted epimerization of *cis*-arylated products to corresponding *trans*-diastereomers **3a** and **18** at 100 °C (Scheme 4).

A 24 h heating time promoted the majority of the *cis*-isomer to epimerize, with a 70% conversion of the *cis* *p*-methoxyphenyl-substituted piperidine and a 90% conversion of the *cis* *p*-bromophenyl substituted substrate, to afford *trans* products **3a** and **18** in 54% and 53% isolated yields, respectively.

Finally, the directing group was removed to unveil polar functionalities and access fragments and building blocks of interest for drug discovery programs (Scheme 5).[37] Boc-activation of amide **2a** and treatment of intermediate **19** with lithium hydrogen peroxide[38] afforded *cis*-carboxylic acid **21** in 71% yield (over 2 steps). Reduction of the same intermediate **19** with $LiAlH_4$ gave alcohol **20** in 62% yield. Alternatively, alcohol **20** could be accessed by reduction of **21** using $BH_3 \cdot SMe_2$. Acid **21** was converted to primary amide **22** by anhydride formation with isobutyl chloroformate, followed by treatment with aqueous NH_4OH.[39] Notably, conversion of **2a** to the primary amide **22** using IBX[40] or ozonolysis[41] conditions was unsuccessful due to alternative oxidation of the electron-rich PMP substituent. A Pd-catalyzed dehydration of amide **22** gave the corresponding nitrile in 77% yield.[42] Acid-mediated Boc deprotection allowed the isolation of HCl salts **23**–**26** in excellent yields. Starting from 2–3 mmol of **2a**, useful quantities (50–80 mg) of fragment compounds were rapidly synthesized, highlighting the practical applications of this methodology.

In summary, we have demonstrated an efficient stereoselective C(3) mono-*cis* functionalization of piperidines and tetrahydropyran bearing a C(4) aminoquinoline directing group. As key features, lower reaction temperatures (45–50 °C) were employed, ensuring high stereocontrol, whilst the use of Mes-



Scheme 4. One-pot arylation-epimerization protocol. Products were isolated as single *trans* diastereomers, with the dr reflecting the ratio between *trans* and *cis* isomers in the crude reaction mixture.



Scheme 5. Divergent aminoquinoline removal. AlogP and Polar Surface Area (PSA) calculated using Llama.[43] Molecular weights corresponding to the free amines.

© 2022 The Authors. Advanced Synthesis & Catalysis published by Wiley-VCH GmbH

COOH additive achieved high levels of starting material conversion of up to 95%. A DoE study generated reaction conditions that minimized the competing diarylation and epimerization processes resulting in high stereoselectivity and an overall reduction in the amounts of reagents used. Additionally, single mono-*trans* diastereomers could be directly accessed through a one-pot arylation-epimerization protocol. Using mild conditions, the aminoquinoline directing group could be removed in a divergent manner. The *N*-Boc protected aminoquinoline amide intermediate was used to unveil alcohol, carboxylic acid, amide and nitriles functionalities. The obtained products afforded fragments with desirable physicochemical properties for fragment-based drug discovery. Valuable fragments of this defined substitution pattern featuring a polar ring heteroatom, a C(4) polar functional group, and a C(3) aryl group were accessed in only 3–4 high-yielding steps from inexpensive commercial materials.[44,45]

Experimental Section

General Procedure for the *cis* C–H arylation of N-Protected Piperidines

A reaction tube was charged with amide **1** (142 mg, 0.40 mmol, 1.0 equiv). The requisite aryl iodide (0.80 mmol, 2.0 equiv), Ag_2CO_3 (138 mg, 0.50 mmol, 1.25 equiv), 2,4,6-trimethylbenzoic acid (MesCOOH, 20 mg, 0.12 mmol, 0.3 equiv) and $Pd(OAc)_2$ (9 mg, 0.04 mmol, 0.1 equiv) were added sequentially. The reaction vessel was sealed and purged with argon, then $PhCF_3$ (1.34 mL, 0.3 M) was added by syringe. The reaction tube was placed in a preheated oil bath and stirred at 45 °C for 24 h. The reaction mixture was then allowed to cool to rt, diluted with EtOAc (5 mL) and filtered through a pad of Celite, eluting with further EtOAc (2 × 10 mL). The solvent was removed under reduced pressure and the crude material purified by flash column chromatography under the specified conditions. The isolated *cis*-3-arylated derivative was azeotroped by addition of Et_2O (5 mL), followed by pentane (5 mL), then concentration of the resulting suspension under reduced pressure. The procedure was repeated three times in order to eliminate residual solvent.

Representative Procedure for the Gram-Scale Synthesis of mono-*cis* Arylated Piperidine 2 a

A round bottom flask (100 mL recommended volume) was charged with amide **1** (1.42 g, 4.00 mmol, 1.0 equiv), then 4-iodoanisole (1.87 g, 8.00 mmol, 2.0 equiv), Ag_2CO_3 (1.38 g, 5.00 mmol, 1.25 equiv), 2,4,6-trimethylbenzoic acid (MesCOOH, 197 mg, 1.2 mmol, 0.3 equiv) and $Pd(OAc)_2$ (90 mg, 0.4 mmol, 0.1 equiv) were added sequentially. The reaction vessel was covered with a suba seal and purged with argon, then $PhCF_3$ (13.4 mL, 0.3 M) was added by syringe. The reaction flask was then placed in a preheated oil bath and stirred at 45 °C for 18 h under an atmosphere of Ar. The reaction mixture was then allowed to cool to rt and EtOAc (20 mL) was added. The resulting mixture was filtered through a pad of Celite, eluting with further EtOAc (2 × 50 mL). The solvent was removed under reduced pressure. The reaction mixture was purified by automated flash column chromatography (2% to 20% acetone/pentane, see *Supporting Information*). The product containing fractions were combined and the solvent was removed under reduced pressure. Et_2O (5 mL) and pentane (10 mL) were added and the solvent was removed under reduced pressure to afford arylated pyrrolidine **2 a** as a white solid (1.34 g, 2.91 mmol, 70%). R_f 0.34 (20% acetone/pentane); mp = 135–137 °C (from Et_2O/pentane); IR (film)/cm^{-1} 3348 (NH br), 2933, 2974, 1681 (C=O), 1528, 1483, 1423, 1245 (C–O), 1163 (C–O), 910, 828, 731; ^1H NMR (500 MHz, DMSO-d_6, 373 K) δ 9.62 (br s, 1 H, NH), 8.80 (dd, J = 4.2, 1.7 Hz, 1 H, HC_{Ar}), 8.46 (dd, J = 7.7, 1.4 Hz, 1 H, HC_{Ar}), 8.31 (dd, J = 7.7, 1.5 Hz, 1 H, HC_{Ar}), 7.58 (dd, J = 8.3, 1.3 Hz, 1 H, HC_{Ar}), 7.55 (dd, J = 8.3, 4.2 Hz, 1 H, HC_{Ar}), 7.50 (t, J = 7.9 Hz, 1 H, HC_{Ar}), 7.22–7.17 (m, 2 H, HC_{Ar}), 6.72–6.66 (m, 2 H, HC_{Ar}), 4.00 (dd, J = 13.0, 8.1 Hz, 1 H, NC*H*HCHAr), 3.82 (ddd, J = 12.9, 8.6, 3.8 Hz, 1 H, NC*H*HCH$_2$), 3.73 (dd, J = 13.0, 4.1 Hz, 1 H, NCH*H*CHAr), 3.58 (s, 3 H, OCH_3), 3.54 (ddd, J = 12.7, 7.0, 4.7 Hz, 1 H, NCH*H*CH$_2$), 3.31 (ddd, J = 6.3, 4.7, 4.5 Hz, 1 H, CH(C=O)), 3.23 (ddd, J = 8.7, 6.7, 4.1 Hz, 1 H, CHAr), 2.05 (ddt, J = 13.1, 6.5, 3.8 Hz, 1 H, NCH$_2$C*H*H), 1.90 (ddt, J = 13.3, 8.6, 4.6 Hz, 1 H, NCH$_2$CH*H*), 1.43 (s, 9 H, C(CH$_3$)$_3$); ^{13}C NMR (126 MHz, DMSO-d_6, 373 K) δ 171.4 (C=O amide), 157.6 (C_{Ar} quat), 153.7 (C=O carbamate), 147.9 (C_{Ar}), 137.6 (C_{Ar} quat), 135.7 (C_{Ar}), 133.7 (C_{Ar} quat), 132.6 (C_{Ar} quat), 128.3 (2 × C_{Ar}), 127.2 (C_{Ar} quat), 126.2 (C_{Ar}), 121.3 (C_{Ar}), 121.0 (C_{Ar}), 115.9 (C_{Ar}), 113.2 (2 × C_{Ar}), 78.2 (*C*(CH$_3$)$_3$), 54.4 (O*C*H$_3$), 45.43 (N*C*H$_2$CHAr), 45.36 (*C*H(C=O)), 41.4 (*C*HAr), 40.5 (N*C*H$_2$CH$_2$), 27.7 (C(*C*H$_3$)$_3$), 25.6 (NCH$_2$*C*H$_2$); HRMS (ESI) *m/z* Calculated for $C_{27}H_{32}N_3O_4$ [M + H] 462.2393; Found 462.2388.

One-Pot Arylation Epimerization: Representative Procedure for Accesssing 3,4-*trans*-Disubstituted Piperidine 3 a

A flame-dried microwave vial (25 mL) was charged sequentially with amide **1** (710 mg, 2.00 mmol, 1.0 equiv), 4-iodoanisole (936 mg, 4.00 mmol, 2.0 equiv), Ag_2CO_3 (690 mg, 2.50 mmol, 1.25 equiv), MesCOOH (99 mg, 0.60 mmol, 0.3 equiv) and $Pd(OAc)_2$ (45.0 mg, 0.20 mmol, 0.1 equiv) in this order. The reaction vessel was sealed and purged with argon, then $PhCF_3$ (6.7 mL, 0.3 M) was added by syringe. The reaction tube was placed in a preheated oil bath and stirred at 45 °C for 24 h. The reaction mixture was then allowed to cool to rt and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU, 0.9 mL, 6.00 mmol, 3.0 equiv) was added by syringe. The reaction vessel was then stirred at 110 °C for additional 24 h. The reaction was allowed to cool to rt and EtOAc (20 mL) was added. The resulting mixture was filtered through a pad of Celite, eluting with further EtOAc (2 × 50 mL). The solvent was removed under reduced pressure, and the crude material was purified by flash column chromatography (5% to 20% acetone/pentane) to afford a mixture of mono-*trans* arylated piperidine **3 a** and di-*cis*-*cis* arylated piperidine **5 a**. A second purification by column chromatography (10% Et_2O/CH_2Cl_2) was conducted and the fractions containing the *trans*-product were combined and concentrated under reduced pressure. Et_2O (10 mL) and

These are not the final page numbers! ↗↗
© 2022 The Authors. Advanced Synthesis & Catalysis published by Wiley-VCH GmbH

pentane (10 mL) were added and the solvent was removed under reduced pressure to afford the *trans*-arylated piperidine **3 a** as a white powder (498 mg, 1.08 mmol, 54%). R_f 0.37 (10% Et_2O/CH_2Cl_2); mp = 99–101 °C (from Et_2O/pentane); IR (film)/ cm^{-1} 3347 (NH br), 3045, 2931, 2858, 2837, 1663 (C=O), 1526, 1485, 1422, 1366, 1245, 1157, 926, 732; ^{1}H NMR (400 MHz, DMSO-d_6, 373 K) δ 9.71 (br s, 1 H, NH), 8.86 (dd, J = 4.2, 1.7 Hz, 1 H, HC_{Ar}), 8.43 (dd, J = 7.7, 1.4 Hz, 1 H, HC_{Ar}), 8.34–8.28 (m, 1 H, HC_{Ar}), 7.57 (ddd, J = 8.3, 2.8, 1.5 Hz, 2 H, HC_{Ar}), 7.46 (dd, J = 7.9, 7.8 Hz, 1 H, HC_{Ar}), 7.33–7.23 (m, 2 H, HC_{Ar}), 6.83–6.74 (m, 2 H, HC_{Ar}), 4.13 (ddd, J = 11.0, 4.3, 2.2 Hz, 1 H, NC*H*HCH$_2$), 4.00 (dd, J = 10.1, 8.8 Hz, 1 H, NC*H*HCHAr), 3.62 (s, 3 H, OCH_3), 3.22 (td, J = 11.4, 3.7 Hz, 1 H, CH(C=O)), 3.02–2.99 (m, 1 H, NCH*H*CH$_2$), 2.95–2.85 (m, 2 H, NCH*H*CHAr and CHAr), 2.04 (dq, J = 13.2, 3.2 Hz, 1 H, NCH$_2$C*H*H), 1.81–1.64 (m, 1 H, NCH$_2$CH*H*), 1.46 (s, 9 H, C(CH$_3$)$_3$); ^{13}C NMR (101 MHz, DMSO-d_6, 373 K) δ 171.6 (C=O amide), 157.8 (C_{Ar} quat), 153.5 (C=O carbamate), 148.0 (C_{Ar}), 137.6 (C_{Ar} quat), 135.8 (C_{Ar}), 133.8 (C_{Ar} quat), 132.7 (C_{Ar} quat), 128.0 (2 × C_{Ar}), 127.2 (C_{Ar} quat), 126.2 (C_{Ar}), 121.4 (C_{Ar}), 121.1 (C_{Ar}), 115.8 (C_{Ar}), 113.6 (2 × C_{Ar}), 78.4 (*C*(CH$_3$)$_3$), 54.5 (OCH_3), 49.3 (N*C*H$_2$CHAr), 49.1 (*C*H(C=O)), 43.6 (CHAr), 42.6 (N*C*H$_2$CH$_2$), 28.8 (NCH$_2$*C*H$_2$) 27.7 (C-(*C*H$_3$)$_3$); HRMS (ESI) *m/z* Calculated for $C_{27}H_{32}N_3O_4$ [M + H] 462.2393; Found 462.2396.

Acknowledgements

We gratefully acknowledge Abbvie and The Royal Society [University Research Fellowship, UF140161 and URF\R \201019 (to J.A.B.), URF Appointed Grant RG150444; URF Enhancement Grant RGF\EA\180031] for funding. We thank Mr. Peter Haycock and Mr. Corey Fülöp (Imperial College London) for NMR services.

References

[1] E. Vitaku, D. T. Smith, J. T. Njardarson, *J. Med. Chem.* **2014**, *57*, 10257–10274.

[2] a) P. K. Singh, O. Silakari, *ChemMedChem* **2018**, *13*, 1071–1087; b) A. Gomtsyan, *Chem. Heterocycl. Compd.* **2012**, *48*, 7–10.

[3] T. J. Ritchie, S. J. F. Macdonald, S. Peace, S. D. Pickett, C. N. Luscombe, *MedChemComm* **2012**, *3*, 1062–1069.

[4] F. Lovering, J. Bikker, C. Humblet, *J. Med. Chem.* **2009**, *52*, 6752–6756.

[5] M. Congreve, R. Carr, C. Murray, H. A. Jhoti, *Drug Discovery Today* **2003**, *8*, 876–877.

[6] A. Nadin, C. Hattotuwagama, I. Churcher, *Angew. Chem. Int. Ed.* **2012**, *51*, 1114–1122; *Angew. Chem.* **2012**, *124*, 1140–1149.

[7] C. W. Murray, D. C. Rees, *Angew. Chem. Int. Ed.* **2016**, *55*, 488–492; *Angew. Chem.* **2016**, *128*, 498–503.

[8] Selected recent cyclisation examples: a) M. A. Larsen, E. T. Hennessy, M. C. Deem, Y. Lam, J. Saurí, A. C. Sather, *J. Am. Chem. Soc.* **2020**, *142*, 726–732; b) A. J. Boddy, D. P. Affron, C. J. Cordier, E. L. Rivers, A. C. Spivey, J. A. Bull, *Angew. Chem. Int. Ed.* **2019**, *58*, 1458–1462; *Angew. Chem.* **2019**, *131*, 1472–1476; c) Y. Wang, X. Wen, X. Cui, X. P. Zhang, *J. Am. Chem. Soc.* **2018**, *140*, 4792–4796; d) G. Liu, W. Fu, X. Mu, T. Wu, M. Nie, K. Li, X. Xu, W. Tang, *Commun. Chem.* **2018**, *1*, 1–8; e) T. Sandmeier, S. Krautwald, E. M. Carreira, *Angew. Chem. Int. Ed.* **2017**, *56*, 11515–11519; *Angew. Chem.* **2017**, *129*, 11673–11677.

[9] For general reviews on the construction of 6-membered saturated N-heterocycles, including ring expansion strategies see: a) V. A. Palchykov, O. Zhurakovskyi, Chapter Three - One-Pot Reactions of Three-Membered Rings Giving N,O,S-Heterocycles. In *Advances in Heterocyclic Chemistry*; E. F. V., Scriven, C. A. Ramsden, Eds.; Academic Press, 2021; Vol. 133, pp 159–223; b) N. Srivastava, L. Macha, H.-J. Ha, *Org. Biomol. Chem.* **2020**, *18*, 5493–5512.

[10] For selected recent hydrogenation examples, see: a) L.-S. Zheng, F. Wang, X.-Y. Ye, G.-Q. Chen, X. Zhang, *Org. Lett.* **2020**, *22*, 8882–8887; b) B. Qu, H. P. R. Mangunuru, S. Tcyrulnikov, D. Rivalti, O. V. Zatolochnaya, D. Kurouski, S. Radomkit, S. Biswas, S. Karyakarte, K. R. Fandrick, J. D. Sieber, S. Rodriguez, J.-N. Desrosiers, N. Haddad, K. McKellop, S. Pennino, H. Lee, N. K. Yee, J. J. Song, M. C. Kozlowski, C. H. Senanayake, *Org. Lett.* **2018**, *20*, 1333–1337.

[11] For reviews on α-functionalization of piperidines, see: a) E. A. Mitchell, A. Peschiulli, N. Lefevre, L. Meerpoel, B. U. W. Maes, *Chem. Eur. J.* **2012**, *18*, 10092–10142; b) G.-Q. Liu, T. Opatz, Chapter Two - Recent Advances in the Synthesis of Piperidines: Functionalization of Preexisting Ring Systems. In *Advances in Heterocyclic Chemistry*; E. F. V. Scriven, C. A. Ramsden, Eds.; Academic Press, 2018; Vol. 125, pp 107–234; c) For an example of Pd catalysed arylation with N-linked directing group, see: J. E. Spangler, Y. Kobayashi, P. Verma, D. Wang, J.-Q. Yu, *J. Am. Chem. Soc.* **2015**, *137*, 11876–11879.

[12] For selected examples of functionalization of piperidine rings beyond arylation using electrochemical or photoredox methodologies, see: a) T. Feng, S. Wang, Y. Liu, S. Liu, Y. Qiu, *Angew. Chem. Int. Ed.* **2022**, *61*, e202115178; b) N. Holmberg-Douglas, Y. Choi, B. Aquila, H. Huynh, D. A. Nicewicz, *ACS Catal.* **2021**, *11*, 3153–3158; c) A. F. Trindade, E. L. Faulkner, A. G. Leach, A. Nelson, S. P. Marsden, *Chem. Commun.* **2020**, *56*, 8802–8805.

[13] Selected examples of heterocycle functionalization beyond C(2): a) A. F. Trindade, E. L. Faulkner, A. G. Leach, A. Nelson, S. P. Marsden, *Chem. Commun.* **2020**, *56*, 8802–8805; b) A. Millet, P. Larini, E. Clot, O. Baudoin, *Chem. Sci.* **2013**, *4*, 2241–2247; c) B. Sundararaju, M. Achard, G. V. M. Sharma, C. Bruneau, *J. Am. Chem. Soc.* **2011**, *133*, 10340–10343.

[14] a) J. Wencel-Delord, F. Glorius, *Nat. Chem.* **2013**, *5*, 369–375; b) T. Cernak, K. D. Dykstra, S. Tyagarajan, P. Vachal, S. W. Krska, *Chem. Soc. Rev.* **2016**, *45*, 546–576; c) M. J. Caplin, D. J. Foley, *Chem. Sci.* **2021**, *12*, 4646–4660.

© 2022 The Authors. Advanced Synthesis & Catalysis published by Wiley-VCH GmbH

[15] For general reviews of C(sp^3)–H functionalization, see: a) K. Godula, D. Sames, *Science* **2006**, *312*, 67–72; b) J. Yamaguchi, A. D. Yamaguchi, K. Itami, *Angew. Chem. Int. Ed.* **2012**, *51*, 8960–9009; *Angew. Chem.* **2012**, *124*, 9092–9142; c) J. He, M. Wasa, K. S. L. Chan, Q. Shao, J.-Q. Yu, *Chem. Rev.* **2017**, *117*, 8754–8786.

[16] For recent selected examples of C–H functionalization of saturated heterocycles at activated positions, see: a) P. Verma, J. M. Richter, N. Chekshin, J. X. Qiao, J.-Q. Yu, *J. Am. Chem. Soc.* **2020**, *142*, 5117–5125; b) J. E. Spangler, Y. Kobayashi, P. Verma, D.-H. Wang, J.-Q. Yu, *J. Am. Chem. Soc.* **2015**, *137*, 11876–11879; c) J. Ghouilem, C. Tran, N. Grimblat, P. Retailleau, M. Alami, V. Gandon, S. Messaoudi, *ACS Catal.* **2021**, *11*, 1818–1826. Photoredox-catalyzed examples:; d) M. Walker, B. Koronkiewicz, S. Chen, K. N. Houk, J. M. Mayer, J. A. Ellman, *J. Am. Chem. Soc.* **2020**, *142*, 8194–8202; e) R. Grainger, T. D. Heightman, S. V. Ley, F. Lima, C. N. Johnson, *Chem. Sci.* **2019**, *10*, 2264–2271; f) M. H. Shaw, V. W. Shurtleff, J. A. Terrett, J. D. Cuthbertson, D. W. C. MacMillan, *Science* **2016**, *352*, 1304–1308; g) D. T. Ahneman, A. G. Doyle, *Chem. Sci.* **2016**, *7*, 7002–7006.

[17] a) D. Antermite, J. A. Bull, *Synthesis* **2019**, *51*, 3171–3204. For a recent review on the functionalization of nonactivated C(sp^3)–H bonds, see: b) B. Liu, A. M. Romine, C. Z. Rubel, K. M. Engle, B.-F. Shi, *Chem. Rev.* **2021**.

[18] For bidentate directing groups: a) V. G. Zaitsev, D. Shabashov, O. Daugulis, *J. Am. Chem. Soc.* **2005**, *127*, 13154–13155; b) D. Shabashov, O. Daugulis, *J. Am. Chem. Soc.* **2010**, *132*, 3965–3972; c) S. Rej, Y. Ano, N. Chatani, *Chem. Rev.* **2020**, *120*, 1788–1887; d) S. Jerhaoui, F. Chahdoura, C. Rose, J.-P. Djukic, J. Wencel-Delord, F. Colobert, *Chem. Eur. J.* **2016**, *22*, 17397–17406; e) W. R. Gutekunst, P. S. Baran, *J. Am. Chem. Soc.* **2011**, *133*, 19076–19079.

[19] D. P. Affron, O. A. Davis, J. A. Bull, *Org. Lett.* **2014**, *16*, 4956–4959.

[20] a) R. Feng, B. Wang, Y. Liu, Z. Liu, Y. Zhang, *Eur. J. Org. Chem.* **2015**, *2015*, 142–151; b) B. Mondal, B. Roy, U. Kazmaier, *J. Org. Chem.* **2016**, *81*, 11646–11655.

[21] D. P. Affron, J. A. Bull, *Eur. J. Org. Chem.* **2016**, *2016*, 139–149.

[22] R. Parella, S. A. Babu, *J. Org. Chem.* **2015**, *80*, 2339–2355.

[23] a) S. Ye, W. Yang, T. Coon, D. Fanning, T. Neubert, D. Stamos, J.-Q. Yu, *Chem. Eur. J.* **2016**, *22*, 4748–4752; b) Q.-Y. Yu, H.-M. Zhong, W.-W. Sun, S.-J. Zhang, P. Cao, X.-P. Dong, H.-B. Qin, J.-K. Liu, B. Wu, *Asian J. Org. Chem.* **2016**, *5*, 608–612.

[24] a) M. Maetani, J. Zoller, B. Melillo, O. Verho, N. Kato, J. Pu, E. Comer, S. L. Schreiber, *J. Am. Chem. Soc.* **2017**, *139*, 11300–11306; b) O. Verho, M. Maetani, B. Melillo, J. Zoller, S. L. Schreiber, *Org. Lett.* **2017**, *19*, 4424–4427.

[25] V. Hutskalova, P. K. Mykhailiuk, *Org. Biomol. Chem.* **2019**, *17*, 4342–4349.

[26] For a *trans*-arylation of glycosides: N. Probst, G. Grelier, S. Dahaoui, M. Alami, V. Gandon, S. Messaoudi, *ACS Catal.* **2018**, *8*, 7781–7786.

[27] For an example of modular C_β–H/C_α–C activation of saturated heterocycles, see: M. Shang, K. S. Feu, J. C. Vantourout, L. M. Barton, H. L. Osswald, N. Kato, K. Gagaring, C. W. McNamara, G. Chen, L. Hu, S. Ni, P. Fernández-Canelas, M. Chen, R. R. Merchant, T. Qin, S. L. Schreiber, B. Melillo, J.-Q. Yu, P. S. Baran, *Proc. Natl. Acad. Sci. USA* **2019**, *116*, 8721–8727.

[28] a) D. Antermite, D. P. Affron, J. A. Bull, *Org. Lett.* **2018**, *20*, 3948–3952; b) J. A. Coleman, V. Navratna, D. Antermite, D. Yang, J. A. Bull, E. Gouaux, *eLife* **2020**, *9*, e56427.

[29] a) B. F. Van Steijvoort, N. Kaval, A. A. Kulago, B. U. W. Maes, *ACS Catal.* **2016**, *6*, 4486–4490; For alkenylation, see: b) S. Biswas, B. F. Van Steijvoort, M. Waeterschoot, N. R. Bheemireddy, G. Evano, B. U. W. Maes, *Angew. Chem. Int. Ed.* **2021**, *60*, 21988–21996.

[30] a) J. J. Topczewski, P. J. Cabrera, N. I. Saper, M. S. Sanford, *Nature* **2016**, *531*, 220–224; b) P. J. Cabrera, M. Lee, M. S. Sanford, *J. Am. Chem. Soc.* **2018**, *140*, 5599–5606; c) E. Y. Aguilera, M. S. Sanford, *Angew. Chem. Int. Ed.* **2021**, *60*, 11227–11230; d) M. Lee, A. Adams, P. B. Cox, M. S. Sanford, *Synlett* **2019**, *30*, 417–422; Also see:; e) Z. Li, M. Dechantsreiter, S. Dandapani, *J. Org. Chem.* **2020**, *85*, 6747–6760.

[31] M. Wasa, K. S. L. Chan, X.-G. Zhang, J. He, M. Miura, J.-Q. Yu, *J. Am. Chem. Soc.* **2012**, *134*, 18570–18572.

[32] J. He, M. Wasa, K. S. L. Chan, J.-Q. Yu, *J. Am. Chem. Soc.* **2013**, *135*, 3387–3390.

[33] G. Xia, Z. Zhuang, L.-Y. Liu, S. L. Schreiber, B. Melillo, J.-Q. Yu, *Angew. Chem. Int. Ed.* **2020**, *59*, 7783–7787; *Angew. Chem.* **2020**, *132*, 7857–7861.

[34] See supporting information for further details.

[35] W. A. Nack, B. Wang, X. Wu, R. Jiao, G. He, G. Chen, *Org. Chem. Front.* **2016**, *3*, 561–564.

[36] For examples of *trans*-palladacycles, see references 21 and 26. Also see: X. Yang, T.-Y. Sun, Y. Rao, *Chem. Eur. J.* **2016**, *22*, 3273–3277.

[37] For recent review on aminoquinoline removal, see: L. S. Fitzgerald, M. L. O'Duill, *Chem. Eur. J.* **2021**, *27*, 8411–8436.

[38] a) D. A. Evans, P. H. Carter, C. J. Dinsmore, J. C. Barrow, J. L. Katz, D. W. Kung, *Tetrahedron Lett.* **1997**, *38*, 4535–4538; b) Y. Feng, G. Chen, *Angew. Chem. Int. Ed.* **2010**, *49*, 958–961; *Angew. Chem.* **2010**, *122*, 970–973.

[39] T. D. Downes, S. P. Jones, H. F. Klein, M. C. Wheldon, M. Atobe, P. S. Bond, J. D. Firth, N. S. Chan, L. Waddelove, R. E. Hubbard, D. C. Blakemore, C. D. Fusco, S. D. Roughley, L. R. Vidler, M. A. Whatton, A. J.-A. Woolford, G. L. Wrigley, P. O'Brien, *Chem. Eur. J.* **2020**, *26*, 8969–8975.

[40] Z. Zhang, X. Li, M. Song, Y. Wan, D. Zheng, G. Zhang, G. Chen, *J. Org. Chem.* **2019**, *84*, 12792–12799.

[41] M. Berger, R. Chauhan, C. A. B. Rodrigues, N. Maulide, *Chem. Eur. J.* **2016**, *22*, 16805–16808.

© 2022 The Authors. Advanced Synthesis & Catalysis published by Wiley-VCH GmbH

[42] H. Okabe, A. Naraoka, T. Isogawa, S. Oishi, H. Naka, *Org. Lett.* **2019**, *21*, 4767–4770.
[43] I. Colomer, C. J. Empson, P. Craven, Z. Owen, R. G. Doveston, I. Churcher, S. P. Marsden, A. Nelson, *Chem. Commun.* **2016**, *52*, 7209–7212.
[44] A version of this manuscript was deposited on the preprint server ChemRxiv. A.-S. Piticari, D. Antermite, J. I. Higham, J. H. Moore, M. P. Webster, J. A. Bull, *ChemRxiv.* **2021**, DOI: 10.26434/chemrxiv-2021-ks58d.
[45] All characterization data for synthesized compounds can be found at https://data.hpc.imperial.ac.uk/resolve/?doi=10148.

© 2022 The Authors. Advanced Synthesis & Catalysis published by Wiley-VCH GmbH

UPDATES

Stereoselective Palladium-Catalyzed C(sp^3)–H Mono-Arylation of Piperidines and Tetrahydropyrans with a C(4) Directing Group

Adv. Synth. Catal. **2022**, *364*, 1 – 11

A.-S. Piticari, D. Antermite, J. I. Higham, J. H. Moore, M. P. Webster, J. A. Bull*